Regulus Therapeutics
RGLS
#6971
Rank
โ‚ฌ0.47 B
Marketcap
6,93ย โ‚ฌ
Share price
0.00%
Change (1 day)
374.11%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚ฌ44.02 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚ฌ39.21 Million a decrease over its 2023 earnings that were of -โ‚ฌ24.98 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚ฌ44.02 Million12.26%
2024 -โ‚ฌ39.21 Million56.97%
2023 -โ‚ฌ24.98 Million6.51%
2022 -โ‚ฌ23.46 Million2.53%
2021 -โ‚ฌ22.88 Million93.59%
2020 -โ‚ฌ11.82 Million-15.41%
2019 -โ‚ฌ13.97 Million-64.46%
2018 -โ‚ฌ39.3 Million-33.26%
2017 -โ‚ฌ58.89 Million-13.98%
2016 -โ‚ฌ68.46 Million44.77%
2015 -โ‚ฌ47.29 Million-1.63%
2014 -โ‚ฌ48.08 Million203.6%
2013 -โ‚ฌ15.84 Million8.65%
2012 -โ‚ฌ14.58 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
โ‚ฌ7.91 B-19,756.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚ฌ7.72 B-19,287.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ1.61 B-4,114.42%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ11.10 B-27,699.15%๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
โ‚ฌ0.11 B-374.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
-โ‚ฌ92.54 Million 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ6.81 B-17,036.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚ฌ99.86 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA